The 2021 National Organization for Rare Disorders (NORD) Breakthrough Summit saw a number of innovations unveiled for the rare disease community. RareDisease Advisor was there to cover the highlights of […]
CureDuchenne joins forces with NIH, FDA, and private organizations to increase effective gene therapies for rare diseases CureDuchenne is delighted to be a partner in the Accelerating Medicines Partnership Bespoke […]
In WMS 2021’s final day and “late-breaking news” session, Capricor Therapeutics announced positive final data from its Phase 2 HOPE-2 clinical trial in Duchenne patients treated with CAP-1002. HOPE-2 was […]
WMS 2021 on Thursday, September 23rd was a full day of oral and poster presentations, and we’ll highlight some Duchenne clinical trial updates covered. Solid Biosciences – SGT-001 micro-dystrophin gene […]
WMS 2021’s agenda on Wednesday, September 22nd was not so much about specific diseases, but rather major and timely research themes across all of biology. The day started with a […]
Monday, September 20th was the first day of the WMS 2021 Virtual Congress, and a day devoted to symposia sponsored by various companies developing therapeutic treatments for neuromuscular disorders. Most […]
It’s that time of year again, when neuromuscular disease researchers clear their calendars for the Annual International Congress of the World Muscle Society (WMS), the largest conference focused solely on […]
CureDuchenne Cares Advocacy Efforts Succeed in Adding Duchenne to the Social Security Administration Compassionate Allowance List (CAL) Social Security Disability Insurance (SSDI) benefits are a financial lifeline for millions of […]
With recent clinical updates from Pfizer, Sarepta and Audenteson their programs in muscular disorders, the timely Gene Therapy for Muscular Disorders arrives as the only meeting dedicated to overcoming the translational […]
